List of Excipients in API pexidartinib
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing pexidartinib
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Daiichi Sankyo Inc | TURALIO | pexidartinib | 65597-402 | CROSPOVIDONE | 2038-07-24 |
| Daiichi Sankyo Inc | TURALIO | pexidartinib | 65597-402 | FERRIC OXIDE YELLOW | 2038-07-24 |
| Daiichi Sankyo Inc | TURALIO | pexidartinib | 65597-402 | FERROSOFERRIC OXIDE | 2038-07-24 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for pexidartinib
Excipient focus: CROSPOVIDONE
pexidartinib drug variants containing CROSPOVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| Daiichi Sankyo Inc | pexidartinib | 65597-402 |
| Daiichi Sankyo Inc | pexidartinib hydrochloride | 65597-407 |
| >Company | >Ingredient | >NDC |
pexidartinib drug variants not containing CROSPOVIDONE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FD&C BLUE NO. 1
pexidartinib drug variants containing FD&C BLUE NO. 1
| Company | Ingredient | NDC |
|---|---|---|
| Daiichi Sankyo Inc | pexidartinib hydrochloride | 65597-407 |
| >Company | >Ingredient | >NDC |
pexidartinib drug variants not containing FD&C BLUE NO. 1
| Company | Ingredient | NDC |
|---|---|---|
| Daiichi Sankyo Inc | pexidartinib | 65597-402 |
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
pexidartinib drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Daiichi Sankyo Inc | pexidartinib | 65597-402 |
| >Company | >Ingredient | >NDC |
pexidartinib drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Daiichi Sankyo Inc | pexidartinib hydrochloride | 65597-407 |
| >Company | >Ingredient | >NDC |
Excipient focus: FERROSOFERRIC OXIDE
pexidartinib drug variants containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Daiichi Sankyo Inc | pexidartinib | 65597-402 |
| >Company | >Ingredient | >NDC |
pexidartinib drug variants not containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Daiichi Sankyo Inc | pexidartinib hydrochloride | 65597-407 |
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE
pexidartinib drug variants containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| Daiichi Sankyo Inc | pexidartinib | 65597-402 |
| Daiichi Sankyo Inc | pexidartinib hydrochloride | 65597-407 |
| >Company | >Ingredient | >NDC |
pexidartinib drug variants not containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
pexidartinib drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Daiichi Sankyo Inc | pexidartinib | 65597-402 |
| Daiichi Sankyo Inc | pexidartinib hydrochloride | 65597-407 |
| >Company | >Ingredient | >NDC |
pexidartinib drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MANNITOL
pexidartinib drug variants containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| Daiichi Sankyo Inc | pexidartinib | 65597-402 |
| Daiichi Sankyo Inc | pexidartinib hydrochloride | 65597-407 |
| >Company | >Ingredient | >NDC |
pexidartinib drug variants not containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLOXAMER 407
pexidartinib drug variants containing POLOXAMER 407
| Company | Ingredient | NDC |
|---|---|---|
| Daiichi Sankyo Inc | pexidartinib | 65597-402 |
| Daiichi Sankyo Inc | pexidartinib hydrochloride | 65597-407 |
| >Company | >Ingredient | >NDC |
pexidartinib drug variants not containing POLOXAMER 407
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
pexidartinib drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Daiichi Sankyo Inc | pexidartinib | 65597-402 |
| Daiichi Sankyo Inc | pexidartinib hydrochloride | 65597-407 |
| >Company | >Ingredient | >NDC |
pexidartinib drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch